How often do people with lurbinectedin have allergic reactions?
I don’t have enough provided information to quantify the prevalence of “lurbinectedin allergies” (e.g., how many patients experience hypersensitivity/allergic reactions) for you.
What side effects are counted as “lurbinectedin allergies” in safety reports?
In clinical safety reporting, the term “allergy” can include different categories such as:
- hypersensitivity reactions,
- infusion-related reactions,
- rash or other drug eruptions,
- anaphylaxis or severe allergic reactions.
Different trials and labels may report these separately, so the “prevalence of allergies” depends on which of these categories you mean.
Where to find the exact prevalence number
The exact prevalence is typically reported in the drug’s prescribing information (clinical trials safety tables and adverse event frequencies). If you share either the country/label you’re using or the specific adverse-event term you mean (for example, “hypersensitivity,” “allergic reaction,” “anaphylaxis,” or “rash”), I can help you locate and interpret the relevant frequency from that labeling.
Also, if you want, tell me whether you’re asking about:
- the general patient population in trials, or
- a specific cancer indication/regimen (since incidence can vary by study).
Quick next step
Reply with one of the following so I can answer precisely:
1) the prescribing information wording you’re using (or a screenshot/text), or
2) what you mean by “allergy” (hypersensitivity? infusion reaction? rash? anaphylaxis?), and
3) the dosing context (brand label/regimen, if known).